Latest filing published 22 Nov 2022 for Acadia Pharmaceuticals INC, €27k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Srdjan R. Stankovic: trading record in brief
Srdjan R. Stankovic (senior executive) discloses dealings in Acadia Pharmaceuticals Inc to SEC (Form 4). The record holds 52 filings, for trades running from 15 October 2019 to 21 November 2022.
The open-market record consists of 23 sales worth €17.0M, with no purchase. Besides market trades, the filings include 1 share grant and 28 option exercises. 2022 to date brings no purchases and 5 sales.
The record was last updated on 22 November 2022 with an open-market sale (€27k) in Acadia Pharmaceuticals Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Srdjan R. Stankovic
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,847 shares@ US$15.0755.6% of flowCommon StockSEC:0001209191-22-058391:1
- 6,250 sharesCommon StockSEC:0001209191-22-058391:0
- 1,326 shares@ US$15.8144.4% of flowCommon StockSEC:0001209191-22-054027:1
- 2,969 sharesCommon StockSEC:0001209191-22-054027:0
- 9,616 sharesCommon StockSEC:0001209191-22-026940:0
- 4,919 shares0Common StockSEC:0001209191-22-013275:0
- 5,444 sharesCommon StockSEC:0001209191-22-002749:0
- 6,250 sharesCommon StockSEC:0001209191-21-066570:0
- 2,969 sharesCommon StockSEC:0001209191-21-060958:0
9 of 9 declarations
